Viatris, a drugmaker formerly known as Mylan Pharmaceuticals, on Feb. 28 agreed to pay $264 million to settle a class-action lawsuit over EpiPen pricing, The Hill reported.
Read the full post on Becker's Hospital Review - Healthcare News
Viatris to pay $264M to settle EpiPen lawsuit
